LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis

Wang, Xiaokang; Wu, Shao-Guo; Yang, Yi; Zhao, Jingjing

doi:10.1155/2022/9277360

Cited by 9 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repression of miR-29a has been mediated by MYC; MYC amplification represents one of the earliest events in HCC development [137,138]. Recent bioinformatics analysis proposed hsa-miR-192-5p as a potential LOXL2 regulator in HCC; however, more in vivo studies are required to clarify these interactions between LOXL2 and specific micro-RNAs in the pathogenesis of HCC [139].…”

Section: Loxl2 and Micro-rnas In Hccmentioning

confidence: 99%

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting

Radic

Kožik

Nikolić

et al. 2023

IJMS

View full text Add to dashboard Cite

LOXL2, a copper-dependent amine oxidase, has emerged as a promising therapeutic target in hepatocellular carcinoma (HCC). Increased LOXL2 expression in HCC has been linked with an aggressive phenotype and represents a poor prognostic factor. Here, we focus on the mechanisms through which LOXL2 orchestrates multiple oncogenic functions in HCC development. We performed a review of the current knowledge on the roles LOXL2 performs in the modulation of the HCC tumor microenvironment, formation of premetastatic niches, and epithelial–mesenchymal transition. We also highlighted the complex interplay between LOXL2 and hypoxia, angiogenesis, and vasculogenic mimicry in HCC. At the end of the review, we summarize the current LOXL2 inhibitors and discuss their potential in HCC precision treatment.

show abstract

Section: Loxl2 and Micro-rnas In Hccmentioning

confidence: 99%

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting

Radic

Kožik

Nikolić

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In colorectal cancer cells, LINC01347 enhances LOXL2 expression by competing with miR-328, resulting in an increase in cell proliferation and chemotherapy resistance [ 88 ]. On the other hand, prediction studies suggest that the lncRNA CARM-mirR-192-LOXL2 axis is associated with poor overall survival, immune infiltration, and immune checkpoint expression in hepatocellular carcinoma [ 89 ].…”

Section: Control Of Loxl2 Expressionmentioning

confidence: 99%

LOXL2 in Cancer: A Two-Decade Perspective

Cano,

Eraso,

Mazón

et al. 2023

IJMS

View full text Add to dashboard Cite

Lysyl Oxidase Like 2 (LOXL2) belongs to the lysyl oxidase (LOX) family, which comprises five lysine tyrosylquinone (LTQ)-dependent copper amine oxidases in humans. In 2003, LOXL2 was first identified as a promoter of tumour progression and, over the course of two decades, numerous studies have firmly established its involvement in multiple cancers. Extensive research with large cohorts of human tumour samples has demonstrated that dysregulated LOXL2 expression is strongly associated with poor prognosis in patients. Moreover, investigations have revealed the association of LOXL2 with various targets affecting diverse aspects of tumour progression. Additionally, the discovery of a complex network of signalling factors acting at the transcriptional, post-transcriptional, and post-translational levels has provided insights into the mechanisms underlying the aberrant expression of LOXL2 in tumours. Furthermore, the development of genetically modified mouse models with silenced or overexpressed LOXL2 has enabled in-depth exploration of its in vivo role in various cancer models. Given the significant role of LOXL2 in numerous cancers, extensive efforts are underway to identify specific inhibitors that could potentially improve patient prognosis. In this review, we aim to provide a comprehensive overview of two decades of research on the role of LOXL2 in cancer.

show abstract

“…Specifically, miR29-a has been identified as a negative regulator of hypoxia-responsive genes such as HIF-1α, VEGFa, LOX, and LOXL2 in HCC cell line and HCC tissue functional studies [63,117]. Recent bioinformatics analysis proposed hsa-mir-192-5p as a potential LOXL2 regulator in HCC, however, more in vivo studies are necessary to clarify interactions between LOXL2 and specific micro-RNAs in HCC pathogenesis [118].…”

Section: Loxl2 and Micro-rnas In Hccmentioning

confidence: 99%

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Potential for Therapeutic Targeting

Radic¹,

Kožik²,

Nikolić³

et al. 2023

Preprint

View full text Add to dashboard Cite

LOXL2, a copper-dependent amine oxidase, has emerged as a promising therapeutic target in hepatocellular carcinoma (HCC). Increased LOXL2 expression in HCC has been linked with aggressive phenotype and represents a poor prognostic factor. Here, we focus on mechanisms by which LOXL2 orchestrates multiple oncogenic functions in HCC development. We are reviewing current knowledge about the roles of LOXL2 in the modulation of the HCC tumor microenvironment, formation of premetastatic niches, and epithelial-mesenchymal transition. Also, we are highlighting the complex interplay between LOXL2 and hypoxia, angiogenesis, and vasculogenic mimicry in HCC. At the end of the review, we summarize current LOXL2 inhibitors and discuss their potential in HCC precision treatment.

show abstract

LncRNA CARMN Affects Hepatocellular Carcinoma Prognosis by Regulating the miR-192-5p/LOXL2 Axis

Cited by 9 publications

References 42 publications

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting

LOXL2 in Cancer: A Two-Decade Perspective

Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Potential for Therapeutic Targeting

Contact Info

Product

Resources

About